PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100201600021C — INCORPORATE FAR DEVIATION CLAUSE 52.223-99, ENSURING ADEQUATE COVID SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS

INCORPORATE FAR DEVIATION CLAUSE 52.223-99, ENSURING ADEQUATE COVID SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS is a federal NONE award for Department of Health and Human Services (HHS) held by MAPP BIOPHARMACEUTICAL, INC.. Estimated value $30.9M ($1.2M obligated). Current period of performance ends Dec 31, 2027. Last award drew 1 bidder.

$30.9M
Estimated Value
$1.2M
Obligated
Dec 31, 2027
PoP End / Expires
1
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

MAPP BIOPHARMACEUTICAL, INC. holds $72.2M across 13 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Dec 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract numberHHSO100201600021C
AgencyDepartment of Health and Human Services (HHS)
IncumbentMAPP BIOPHARMACEUTICAL, INC.
UEIM9V9QTHR1H28
NAICS541720

No full NAICS 541720 intel page yet. Browse NAICS intelligence

PSCAN12
PoP end (current)Dec 31, 2027
Obligated$1.2M

INCORPORATE FAR DEVIATION CLAUSE 52.223-99, ENSURING ADEQUATE COVID SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS

Recompete timing

Public
Expiring in 501 days

Current PoP ends Dec 31, 2027 (501 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jul 1, 2026.

Watch this contract — one email →

Incumbent footprint

Public record

MAPP BIOPHARMACEUTICAL, INC.$72.2M obligated across 13 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($72.2M) · all agencies
Department of Health and Human Services (HHS)$72.1M · 100%Department of Defense (DOD)$92K · 0%
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for HHSO100201600021C
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open MAPP BIOPHARMACEUTICAL, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract HHSO100201600021C?

HHSO100201600021C (INCORPORATE FAR DEVIATION CLAUSE 52.223-99, ENSURING ADEQUATE COVID SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS) is a Department of Health and Human Services (HHS) award with an estimated value of $30.9M, currently held by MAPP BIOPHARMACEUTICAL, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on HHSO100201600021C?

MAPP BIOPHARMACEUTICAL, INC. is the incumbent with $72.2M across 13 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2027.

When does HHSO100201600021C come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HHSO100201600021C